WCN26-7992 ASSESSING THE EFFICACY AND SAFETY OF RITUXIMAB IN TREATING CHILDHOOD-ONSET STEROID-DEPENDENT NEPHROTIC SYNDROME: A SYSTEMATIC REVIEW OF RCTs

Read full text Summarise with VIRAT
Authors: Jessica Pricilla Tanojo, Louise Nadya Victoria Hawun Tingkes, Agustine Monica Susilo, Keyla Nadhira Suseno, Serafina Tegu, Novella Auerellin SP, Angelina Wandana, Jeremia Immanuel Siregar, Andree Kurniawan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Nephrotic syndrome (NS) is one of the most prevalent chronic glomerular diseases in pediatric patients, with an annual incidence of 2 to 7 cases per 100,000 children. Despite its rarity, NS remains a concern as it can lead to end-stage renal disease (ESRS). Although most patients attain remission after corticosteroid therapy, the first in-line treatment for NS, 50% of patients develop frequent relapse nephrotic syndrome (FRNS). The current key objective of NS treatment is to avoid relapses while minimizing drug side effects.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105634–105634
Publication date
25 March 2026
Language
EN